A light-activated nickel(ii)–antibiotic conjugate for synergistic antibacterial therapy

Abstract

Herein, we report a molecular conjugate, Ni-1-Cip, by linking the antibiotic ciprofloxacin to a Ni(II) scaffold for treatment of multidrug-resistant (MDR) bacterial infections using photothermal therapy (PTT). The localized hyperthermia generated by the Ni(II) core potentiates the antibacterial activity of the ciprofloxacin, leading to eradication of methicillin-resistant S. aureus (MRSA) as demonstrated in a murine model.

Graphical abstract: A light-activated nickel(ii)–antibiotic conjugate for synergistic antibacterial therapy

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Communication
Submitted
21 Nov 2025
Accepted
13 Jan 2026
First published
14 Jan 2026

Chem. Commun., 2026, Advance Article

A light-activated nickel(II)–antibiotic conjugate for synergistic antibacterial therapy

R. Zhang, Y. Zhou, Z. Lin, X. Huang, J. Zhang, S. Gao and J. Zhang, Chem. Commun., 2026, Advance Article , DOI: 10.1039/D5CC06624G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements